154 related articles for article (PubMed ID: 7921925)
1. Interleukin-3 in combination with granulocyte-macrophage-colony-stimulating factor following bone marrow transplantation in a radiation accident victim.
Nagler A; Naparstek E; Drakos P; Brautbar C; Goldman M; Kaplan O; Fridmann A; Slavin S
Med Oncol; 1994; 11(1):27-8. PubMed ID: 7921925
[No Abstract] [Full Text] [Related]
2. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
[TBL] [Abstract][Full Text] [Related]
3. Failure of interleukin-1 and granulocyte-macrophage colony-stimulating factor to enhance allogeneic marrow engraftment and survival in irradiated dogs.
Mathey B; Yu C; Sandmaier BM; Deeg HJ; Graham T; Schuening FG; Nash RA; Stor B
Blood; 1995 Jul; 86(2):833-4. PubMed ID: 7606016
[No Abstract] [Full Text] [Related]
4. Use of hematopoietic growth factors in marrow transplantation.
Nemunaitis J
Curr Opin Oncol; 1994 Mar; 6(2):139-45. PubMed ID: 7516712
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma.
Fay JW; Bernstein SH
Semin Oncol; 1996 Apr; 23(2 Suppl 4):22-7. PubMed ID: 8600545
[TBL] [Abstract][Full Text] [Related]
6. Recombinant hematopoietic growth factors in bone marrow transplantation.
Nemunaitis J
Cancer Treat Res; 1995; 76():225-48. PubMed ID: 7577337
[No Abstract] [Full Text] [Related]
7. Use of recombinant human granulocyte-macrophage colony stimulating factor in an infant with reticular dysgenesis.
Azcona C; Alzina V; Barona P; Sierrasesúmaga L; Villa-Elízaga I
Eur J Pediatr; 1994 Mar; 153(3):164-6. PubMed ID: 8181497
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
[TBL] [Abstract][Full Text] [Related]
9. Marketing of recombinant granulocyte-macrophage colony-stimulating factor approved by FDA.
Clin Pharm; 1991 Jun; 10(6):411. PubMed ID: 2065520
[No Abstract] [Full Text] [Related]
10. Cytokine-mobilized peripheral blood progenitor cells.
Nemunaitis J
Semin Oncol; 1996 Apr; 23(2 Suppl 4):9-14. PubMed ID: 8600547
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
[TBL] [Abstract][Full Text] [Related]
12. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO
Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592
[TBL] [Abstract][Full Text] [Related]
13. The myeloid colony-stimulating factors: introduction and overview.
Peters WP
Semin Hematol; 1991 Apr; 28(2 Suppl 2):1-5. PubMed ID: 1712123
[No Abstract] [Full Text] [Related]
14. The role of hematopoietic growth factors in the treatment of neoplastic diseases.
St Onge J; Jacobson RJ
Semin Hematol; 1992 Jul; 29(3 Suppl 2):53-63. PubMed ID: 1380737
[No Abstract] [Full Text] [Related]
15. Adjuvant therapy with recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor.
Schulz G; Krumwieh D; Oster W
Pharmacol Ther; 1991 Oct; 52(1):85-94. PubMed ID: 1805248
[TBL] [Abstract][Full Text] [Related]
16. Severe idiopathic congenital aplastic anemia: role of hematopoietic growth factors.
Vermylen C; Cornu G; DeWitte M; Heremans MT; Ninane J; Brichard B
Bone Marrow Transplant; 1993 Oct; 12(4):413-5. PubMed ID: 8275043
[TBL] [Abstract][Full Text] [Related]
17. Remission of juvenile chronic myeloid leukemia following graft failure of an unrelated marrow transplant and autologous recovery of marrow function promoted by GM-CSF and IL-3.
Suttorp M; Schmitz N; Prange E; Oster W; Löffler H; Schaub J; Ganser A
Leukemia; 1991 Aug; 5(8):723-5. PubMed ID: 1886426
[TBL] [Abstract][Full Text] [Related]
18. The role of bone marrow transplantation in the treatment of myelodysplastic syndromes.
Schultz AB; Geller RB; Hillyer CD
J Hematother; 1995 Aug; 4(4):323-34. PubMed ID: 7489147
[No Abstract] [Full Text] [Related]
19. Clinical trials of myeloid growth factors.
Glaspy JA; Golde DW
Exp Hematol; 1990 Nov; 18(10):1137-41. PubMed ID: 1698650
[No Abstract] [Full Text] [Related]
20. Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro.
Estrov Z; Kurzrock R; Talpaz M; Blake M; Gutterman JU
Ann Hematol; 1991 Dec; 63(6):297-301. PubMed ID: 1756190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
